Literature DB >> 19675543

From trial and error to trial simulation. Part 2: an appraisal of current beliefs in the design and analysis of clinical trials for antidepressant drugs.

G Santen1, J Horrigan, M Danhof, O Della Pasqua.   

Abstract

Study design factors are partly to blame for the high failure rate in trials with antidepressant drugs. Clinical trial simulation (CTS) allows the investigation of the influence of design characteristics on important aspects of clinical trials such as power and type I error. Using CTS scenarios, we evaluated the impact of population size, randomization ratio, frequency of assessments, dropout mechanisms, clinical end point, and statistical method on the outcome of clinical trials with antidepressant drugs. The results reveal that (i) an increase in the frequency of visits does not increase statistical power, (ii) a skewed randomization for a placebo or comparator arm may decrease statistical power, and (iii) analysis of the percentage of responders should be avoided. CTS should become best practice in the optimization of study design. To date, no other statistical approach has enabled such comprehensive evaluation of the factors contributing to study failure in depression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19675543     DOI: 10.1038/clpt.2009.107

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

1.  Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis.

Authors:  Tarjinder Sahota; Oscar Della Pasqua
Journal:  Antimicrob Agents Chemother       Date:  2012-07-09       Impact factor: 5.191

2.  Population Pharmacokinetics: Some Observations in Pediatric Modeling for Drug Clearance.

Authors:  Iftekhar Mahmood; Million A Tegenge
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

3.  Prediction of drug clearance in children: an evaluation of the predictive performance of several models.

Authors:  Iftekhar Mahmood; Carl-Michael Staschen; Kosalaram Goteti
Journal:  AAPS J       Date:  2014-10-02       Impact factor: 4.009

4.  Stratification, Hypothesis Testing, and Clinical Trial Simulation in Pediatric Drug Development.

Authors:  Ann W McMahon; Kevin Watt; Jian Wang; Dionna Green; Ram Tiwari; Gilbert J Burckart
Journal:  Ther Innov Regul Sci       Date:  2016-06-02       Impact factor: 1.778

5.  Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations?

Authors:  Massimo Cella; Wei Zhao; Evelyne Jacqz-Aigrain; David Burger; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2011-09       Impact factor: 4.335

6.  Power behind the throne: A clinical trial simulation study evaluating the impact of controllable design factors on the power of antidepressant trials.

Authors:  Astrid Chevance; Florian Naudet; Raphaël Gaillard; Philippe Ravaud; Raphaël Porcher
Journal:  Int J Methods Psychiatr Res       Date:  2019-04-17       Impact factor: 4.035

Review 7.  Dosing in children: a critical review of the pharmacokinetic allometric scaling and modelling approaches in paediatric drug development and clinical settings.

Authors:  Iftekhar Mahmood
Journal:  Clin Pharmacokinet       Date:  2014-04       Impact factor: 6.447

8.  Prediction of Human Glomerular Filtration Rate from Preterm Neonates to Adults: Evaluation of Predictive Performance of Several Empirical Models.

Authors:  Iftekhar Mahmood; Carl-Michael Staschen
Journal:  AAPS J       Date:  2016-01-22       Impact factor: 4.009

Review 9.  Challenges in translational drug research in neuropathic and inflammatory pain: the prerequisites for a new paradigm.

Authors:  A Taneja; O Della Pasqua; M Danhof
Journal:  Eur J Clin Pharmacol       Date:  2017-09-11       Impact factor: 2.953

Review 10.  How to optimise drug study design: pharmacokinetics and pharmacodynamics studies introduced to paediatricians.

Authors:  Eric Vermeulen; John N van den Anker; Oscar Della Pasqua; Kalle Hoppu; Johanna H van der Lee
Journal:  J Pharm Pharmacol       Date:  2016-09-27       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.